[Clinical observation of thyroid-related adverse events induced by anti-PD-1 antibody SHR-1210 in patients with advanced solid tumor].
Ling Qi(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Huang(Dalian Medical University), Hongnan Mo(Chinese Academy of Medical Sciences & Peking Union Medical College), Bo Lan(Chinese Academy of Medical Sciences & Peking Union Medical College), Qun Li(Sichuan University), Xuelian Chen(Chengdu Medical College), Qing Yang(Guangzhou University of Chinese Medicine), Dawei Wu(Chinese PLA General Hospital), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xi Wang(University of Florida), Xingyuan Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianping Xu(McMaster University)
Cited by 2
Related Papers
Large-scale genome sequencing of mycorrhizal fungi provides insights into the early evolution of symbiotic traits
|Nature Communications|2020|518
Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues: Synthesis, Structure−Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation
|Journal of Medicinal Chemistry|2002|421
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415